Cargando…
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
Autores principales: | Miyazaki, Isao, Odintsov, Igor, Ishida, Keiji, Lui, Allan J. W., Kato, Masanori, Suzuki, Tatsuya, Zhang, Tom, Wakayama, Kentaro, Kurth, Renate I., Cheng, Ryan, Fujita, Hidenori, Delasos, Lukas, Vojnic, Morana, Khodos, Inna, Yamada, Yukari, Ishizawa, Kota, Mattar, Marissa S., Funabashi, Kaoru, Chang, Qing, Ohkubo, Shuichi, Yano, Wakako, Terada, Ryuichiro, Giuliano, Claudio, Lu, Yue Christine, Bonifacio, Annalisa, Kunte, Siddharth, Davare, Monika A., Cheng, Emily H., de Stanchina, Elisa, Lovati, Emanuela, Iwasawa, Yoshikazu, Ladanyi, Marc, Somwar, Romel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597837/ https://www.ncbi.nlm.nih.gov/pubmed/37814012 http://dx.doi.org/10.1038/s43018-023-00663-3 |
Ejemplares similares
-
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
por: Miyazaki, Isao, et al.
Publicado: (2023) -
RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation
por: Hayashi, Takuo, et al.
Publicado: (2021) -
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
por: Somwar, Romel, et al.
Publicado: (2020) -
LPTO-04. GENERATION AND CHARACTERIZATION OF PATIENT-DERIVED PRECLINICAL MODELS FROM TUMOR CELLS ISOLATED FROM CEREBROSPINAL FLUID
por: Offin, Michael, et al.
Publicado: (2019) -
CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma
por: Odintsov, Igor, et al.
Publicado: (2022)